A publication related to bradykinin biology was released on October 9, 2026. Titled "Genome editing for hereditary angioedema: A landmark trial and important unanswered questions," it appeared in the journal Med (New York, N.Y.). The paper is indexed under PubMed ID 42854678.
Hereditary angioedema involves bradykinin pathway activity, and this publication discusses a genome editing trial relevant to that condition. No specific trial results, efficacy data, or safety outcomes were included in the information provided for this brief. The publication is described as addressing both a landmark trial and unresolved questions in the field.
Bradykinin itself remains classified as an unapproved compound for research use. This publication does not constitute regulatory approval or endorsement of any bradykinin-related therapy or genome editing approach. No dosing information, clinical recommendations, or outcome data are included here, consistent with the limited scope of the available event record.
Readers interested in the broader scientific and regulatory context around bradykinin can consult the compound overview for additional background information.